GRMN vs PPCB · P/E 28, rev $6.30B vs P/E 0.0, $3.9M cap
Garmin Ltd (GRMN) versus Propanc Biopharma, Inc. Common Stock (PPCB) — a side-by-side from cached financials, not a winner call.
Garmin Ltd (GRMN) is a scientific & technical instruments company listed on US.
Propanc Biopharma, Inc. Common Stock (PPCB) is a biotechnology company listed on NASDAQ.
Latest reported GRMN revenue for 2024-12-28 was $6.30B. Net income was $1.41B. Revenue was up 20.4% from 2023-12-30 to 2024-12-28. GRMN currently screens at market cap $41.35B and trailing P/E 28.3.
PPCB does not have a complete income-statement cache yet.
GRMN currently screens at market cap $41.35B and trailing P/E 28.3. PPCB currently screens at market cap $3.9M and trailing P/E 0.0.
Not investment advice. Open the GRMN and PPCB stock pages for the full models.
Not investment advice.